The world's leading pharmaceutical company “AstraZeneca” shared the news the FDA called its product "breakthrough" again. This product is the second drug acquired such a status in a short time. The first drug “Imfinzi” has been developed for the treatment of lung cancer, the second one - for the treatment of blood cancer (“Acalabrutinib”).
“Acalabrutinib” is an inhibitor of Bruton tyrosine-kinase (TKB). It has been developed to treat many types of B-cell cancer in patients who have previously received at least one course of therapy.
The “Acalabrutinib” drug was called "breakthrough" by the data of phase II clinical trial ACE-LY-004. Patients with recurrent or refractory mantle cell lymphoma (MRL), an aggressive form of B-cell non-Hodgkin's lymphoma, participated in this research. Also, the new drug test for use as a monotherapy and in combination with other drugs to treat several types of blood cancer, as well as solid/substantial tumours. ”Acalabrutinib” is being studied for the treatment of chronic lymphocytic leukaemia (CLL), and there are preliminary positive results.
Statements on
Link to the original

BaDM - We work for you!